2013
DOI: 10.1371/journal.pone.0059045
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Small Molecule Activators of BMP Signaling

Abstract: Bone Morphogenetic Proteins (BMPs) are morphogens that play a major role in regulating development and homeostasis. Although BMPs are used for the treatment of bone and kidney disorders, their clinical use is limited due to the supra-physiological doses required for therapeutic efficacy causing severe side effects. Because recombinant BMPs are expensive to produce, small molecule activators of BMP signaling would be a cost-effective alternative with the added benefit of being potentially more easily deliverabl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
78
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 63 publications
(78 citation statements)
references
References 51 publications
0
78
0
Order By: Relevance
“…However, it is conceivable that a similar mechanism exists in OligPCs, and that methylation of the BMPR1B promoter in the OligPCs studied by their group accounts for the disparate response they observed. Our study suggests OligPC differentiation via BMP treatment as a viable novel approach to targeted therapy in anaplastic oligodendrogliomas, perhaps taking advantage of newly-developed small molecule BMP agonists (36). An assessment of the tumorigenicity of BMP-treated OligPCs in immunocompromised mice, which was not within the scope of this study, would be of paramount interest.…”
Section: Discussionmentioning
confidence: 91%
“…However, it is conceivable that a similar mechanism exists in OligPCs, and that methylation of the BMPR1B promoter in the OligPCs studied by their group accounts for the disparate response they observed. Our study suggests OligPC differentiation via BMP treatment as a viable novel approach to targeted therapy in anaplastic oligodendrogliomas, perhaps taking advantage of newly-developed small molecule BMP agonists (36). An assessment of the tumorigenicity of BMP-treated OligPCs in immunocompromised mice, which was not within the scope of this study, would be of paramount interest.…”
Section: Discussionmentioning
confidence: 91%
“…To test this hypothesis, we took two approaches to raise BMP signaling activity in early embryos above wild-type levels: (i) injecting 4′-hydroxychalcone, a recently identified chemical activator of the BMP pathway (30), and (ii) injecting recombinant D. melanogaster Decapentaplegic (Dpp) protein (Dm-Dpp) (SI Appendix, Figs. S8 and S9).…”
Section: Resultsmentioning
confidence: 99%
“…However, the utilization of small molecules for engineering musculoskeletal tissues has been largely overlooked. This trend is very likely to be reversed as advanced screening technologies have recently generated a large number of novel regenerative small molecule drugs, and advanced tissue engineering scaffolds continue to provide promise for controllable drug delivery to target tissues [8, 22, 2830]. …”
Section: Small Molecules As Regenerative Medicinementioning
confidence: 99%